The small patient populations of rare diseases, the limited natural history of these conditions, and the lack of long-term experience with new treatments all contribute to the difficulty in determining the value of rare disease therapies. The issue can be further complicated by whether value is calculated in a single payer system, or a multi-payer system. Recently the Innovation and Value Initiative issued a report with the Everylife Foundation for Rare Diseases from a long-term project to bring together stakeholders to explore patient-centered outcomes across rare diseases to inform those discussions. We spoke to Rick Chapman, chief scientific officer of the Innovation and Value Initiative, about the challenges of assessing the value of rare disease therapies, the role qualitative data should play in value assessments, and the recommendations from the report.
Lumos Hopes Its Oral Alternative to HGH Will Fuel Its Growth
Advancing a Gene Therapy for a Rare and Fatal CNS Disorder
Addressing the Barriers to Patient Participation in Clinical Trials
A Venture Philanthropist Makes the Case for Advocates Taking Equity
Seeking a Sustainable Business Developing on N-of-1 Therapies
How One Drugmaker Reaches out to Communities at Greater Risk for Rare Heart Condition
A Next-Generation RNA Therapy Targets Telomere Disorders
BridgeBio Advances Therapy for Limb-Girdle Muscular Dystrophy that Started with Two Patient Families
Translating Urgency into Science
Empowering Ultra-Rare Disease Patients to Pursue the Discovery of Treatments
Why a Topical Cannabidiol Gel May Help Treat the Behavioral Symptoms of Fragile X
An Ultra-Rare Disease Drug Developer Tries to Navigate Regulatory Uncertainty
Powering Cells in People with Rare Mitochondrial Diseases
Powering Weakened and Stressed Cells in ALS to Function Better with Nanocrystal Therapy
Developing a New Class of Therapies Based on a Natural Cargo Carrier
Reaching Beyond the Limits of Enzyme Replacement Therapies with Gene Therapies
One Woman’s Journey as a Caregiver to a Husband with Frontotemporal Dementia
Treating Rare Endocrine Disorders with Therapeutic Peptides
Tackling the Pricing Challenges for Advanced Therapies for Rare Diseases
Addressing the Current Limitations of AAV Gene Therapies
Create your
podcast in
minutes
It is Free
The emPOWERed Half Hour
NABOR® TALKS
U.S Property Podcast
Aligned Money Show
The Ramsey Show
Planet Money